Thrivent Financial for Lutherans
MYGN icon

Thrivent Financial for Lutherans’s Myriad Genetics MYGN Stock Holding History

Thrivent Financial for Lutherans’s Portfolio MYGN Stock Details MYGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$50K Sell
11,214
-64,050
-85% -$334K ﹤0.01% 2517
2025
Q4 		$463K Sell
75,264
-3,076
-4% -$22.3K ﹤0.01% 2282
2025
Q3 		$566K Sell
78,340
-16,436
-17% -$97.6K ﹤0.01% 2037
2025
Q2 		$503K Buy
94,776
+912
+1% +$5.39K ﹤0.01% 2145
2025
Q1 		$833K Sell
93,864
-3,498
-4% -$42K ﹤0.01% 1834
2024
Q4 		$1.33M Sell
97,362
-11,854
-11% -$219K ﹤0.01% 1710
2024
Q3 		$2.99M Sell
109,216
-3,815
-3% -$103K 0.01% 1185
2024
Q2 		$2.77M Sell
113,031
-3,292
-3% -$72.2K 0.01% 1179
2024
Q1 		$2.48M Sell
116,323
-2,205
-2% -$47.4K 0.01% 1255
2023
Q4 		$2.27M Buy
118,528
+2,175
+2% +$37.6K ﹤0.01% 1293
2023
Q3 		$1.87M Sell
116,353
-3,112
-3% -$59.2K ﹤0.01% 1339
2023
Q2 		$2.77M Buy
119,465
+39,159
+49% +$855K 0.01% 1133
2023
Q1 		$1.87M Sell
80,306
-2,814
-3% -$57.1K ﹤0.01% 1341
2022
Q4 		$1.21M Sell
83,120
-234
-0.3% -$4.36K ﹤0.01% 1609
2022
Q3 		$1.59M Buy
83,354
+4,420
+6% +$101K ﹤0.01% 1372
2022
Q2 		$1.43M Buy
78,934
+13,926
+21% +$289K ﹤0.01% 1457
2022
Q1 		$1.64M Buy
65,008
+21
+0% +$537 ﹤0.01% 1469
2021
Q4 		$1.79M Buy
64,987
+1,894
+3% +$54.9K ﹤0.01% 1463
2021
Q3 		$2.04M Buy
63,093
+103
+0.2% +$3.42K ﹤0.01% 1335
2021
Q2 		$1.93M Buy
62,990
+1,207
+2% +$34.9K ﹤0.01% 1445
2021
Q1 		$1.88M Sell
61,783
-470
-0.8% -$13.3K ﹤0.01% 1462
2020
Q4 		$1.23M Buy
62,253
+305
+0.5% +$4.92K ﹤0.01% 1619
2020
Q3 		$808K Sell
61,948
-22,775
-27% -$288K ﹤0.01% 1706
2020
Q2 		$961K Buy
84,723
+59
+0.1% +$838 ﹤0.01% 1526
2020
Q1 		$1.21M Buy
84,664
+25,432
+43% +$537K ﹤0.01% 1187
2019
Q4 		$1.61M Buy
59,232
+383
+0.7% +$10.5K ﹤0.01% 1162
2019
Q3 		$1.69M Buy
58,849
+1,366
+2% +$39.8K 0.01% 1098
2019
Q2 		$1.6M Buy
57,483
+373
+0.7% +$10.5K ﹤0.01% 1121
2019
Q1 		$1.9M Buy
57,110
+4,218
+8% +$128K 0.01% 985
2018
Q4 		$1.54M Sell
52,892
-2,319,634
-98% -$83.4M 0.01% 942
2018
Q3 		$109M Sell
2,372,526
-484,320
-17% -$21.5M 0.34% 60
2018
Q2 		$107M Buy
2,856,846
+8,042
+0.3% +$272K 0.35% 60
2018
Q1 		$84.2M Buy
2,848,804
+38,368
+1% +$1.3M 0.28% 78
2017
Q4 		$96.5M Buy
2,810,436
+836
+0% +$28.2K 0.32% 68
2017
Q3 		$102M Buy
2,809,600
+67,260
+2% +$1.92M 0.36% 62
2017
Q2 		$70.9M Buy
2,742,340
+2,703,860
+7,027% +$57.4M 0.29% 84
2017
Q1 		$739K Buy
+38,480
New +$682K ﹤0.01% 1336
2016
Q3 		– Sell
-26,340
Closed -$806K – 2030
2016
Q2 		$806K Sell
26,340
-6,350
-19% -$221K ﹤0.01% 1194
2016
Q1 		$1.22M Buy
+32,690
New +$1.23M 0.01% 1024
2014
Q3 		– Sell
-35,950
Closed -$1.4M – 1875
2014
Q2 		$1.4M Buy
+35,950
New +$1.34M 0.01% 798

Other funds holding MYGN

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
GCM
Glenview Capital Management New York $3.98B AUM 20.52% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Thrivent Financial for Lutherans's MYGN Position: Q1 2026 in Review

Thrivent Financial for Lutherans reduced its Myriad Genetics (MYGN) stake by 85% in Q1 2026, selling an estimated $334K and leaving 11,214 shares worth $50K. The position accounts for ﹤0.01% of the portfolio, ranked #2517.

Thrivent Financial for Lutherans first reported a position in MYGN in Q2 2014 and has held it in 40 quarters since. The position peaked at $109M in Q3 2018. 202 funds tracked by Wall St. Rank hold MYGN as of Q1 2026.

  • Thrivent Financial for Lutherans held 11,214 shares of Myriad Genetics worth $50K as of Q1 2026.
  • Thrivent Financial for Lutherans sold 64,050 Myriad Genetics shares in Q1 2026, an estimated $334K.
  • Myriad Genetics made up ﹤0.01% of Thrivent Financial for Lutherans's portfolio in Q1 2026, its #2517 holding.
  • Thrivent Financial for Lutherans first reported a position in Myriad Genetics in Q2 2014 and has held it in 40 quarters since.
  • Thrivent Financial for Lutherans's Myriad Genetics position peaked at $109M in Q3 2018.
  • 202 funds tracked by Wall St. Rank held Myriad Genetics as of Q1 2026.

Based on Thrivent Financial for Lutherans's 13F filing for Q1 2026, filed 1 May 2026.